A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans

We have recently described the construction of a galE derivative of Salmonella typhi Ty2 (Ty2H1) which had a 0.4-kilobase deletion in the galE gene and was sensitive to galactose-induced lysis when cultured with greater than or equal to 0.06 mM galactose (D. M. Hone, R. Morona, S. Attridge, and J. Hackett, J. Infect. Dis. 156:167-174, 1987). We now report the selection of a rifampin-resistant, via derivative of Ty2H1, EX462. Compared with the Ty2 parent strain, EX462 was serum sensitive and highly attenuated in the mouse mucin virulence assay. When four human volunteers ingested 7 X 10(8) viable EX462, two became ill and developed a typhoidlike disease with fever and bacteremia. Blood isolates from these individuals were indistinguishable from the vaccine strain by a variety of criteria. We concluded that, even in a via background, the galE mutation was not attenuating for S. typhi in humans.

[1]  S. Attridge,et al.  Construction of defined galE mutants of Salmonella for use as vaccines. , 1987, The Journal of infectious diseases.

[2]  M. F. Edwards,et al.  Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. , 1987, The Journal of clinical investigation.

[3]  R. Chander,et al.  Mechanisms of Acquired Resistance in Mouse Typhoid , 1987, Microbiology and immunology.

[4]  B. Stocker,et al.  Some galE mutants of Salmonella choleraesuis retain virulence , 1986, Infection and immunity.

[5]  M. Levine,et al.  Summary of an international workshop on typhoid fever. , 1986, Reviews of infectious diseases.

[6]  R. Clarke,et al.  Galactose epimeraseless mutants of Salmonella typhimurium as live vaccines for calves. , 1986, Canadian journal of veterinary research = Revue canadienne de recherche veterinaire.

[7]  D. Shearman,et al.  Gut immunity to typhoid: The immune response to a live oral typhoid vaccine Ty21a , 1986 .

[8]  D. Rowley,et al.  The correlation between serum IgA antibody levels and resistance to infection with Salmonella typhimurium after oral immunization with various salmonellae. , 1985, The Australian journal of experimental biology and medical science.

[9]  J. Robbins,et al.  Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. , 1984, The Journal of infectious diseases.

[10]  G. M. Robertson,et al.  Vaccination of sheep with a live gal e mutant of Salmonella typhimurium. , 1982, Australian veterinary journal.

[11]  C. Serié,et al.  A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results. , 1982, The Journal of infectious diseases.

[12]  D. Rowley,et al.  Intestinal Colonization and Virulence of Salmonella in Mice , 1978, Infection and immunity.

[13]  M. Levine,et al.  Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine. , 1977, The Journal of infectious diseases.

[14]  J. Morris,et al.  The immunization of mice and calves with gal E mutants of Salmonella typhimurium , 1977, Journal of Hygiene.

[15]  M. Levine,et al.  Attenuated, streptomycin-dependent Salmonella typhi oral vaccine: potential deleterious effects of lyophilization. , 1976, The Journal of infectious diseases.

[16]  R. Germanier,et al.  Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. , 1975, The Journal of infectious diseases.

[17]  F. Collins,et al.  Growth of Typhoid and Paratyphoid Bacilli in Intravenously Infected Mice , 1974, Infection and immunity.

[18]  F. Collins,et al.  THE ROUTE OF ENTERIC INFECTION IN NORMAL MICE , 1974, The Journal of experimental medicine.

[19]  F. Collins,et al.  Comparative Immunogenicity of Heat-Killed and Living Oral Salmonella Vaccines , 1972, Infection and immunity.

[20]  R. Germanier.  Immunity in Experimental Salmonellosis III. Comparative Immunization with Viable and Heat-Inactivated Cells of Salmonella typhimurium , 1972, Infection and immunity.

[21]  E. Fuerer,et al.  Immunity in Experimental Salmonellosis II. Basis for the Avirulence and Protective Capacity of gal E Mutants of Salmonella typhimurium , 1971, Infection and immunity.

[22]  H. Dupont,et al.  Typhoid fever: pathogenesis and immunologic control. , 1970, The New England journal of medicine.

[23]  R. Germanier.  Immunity in Experimental Salmonellosis I. Protection Induced by Rough Mutants of Salmonella typhimurium , 1970, Infection and immunity.

[24]  S. Saito,et al.  Galactose l-Phosphate Uridylyltransferase of Escherichia coli II. FURTHER PURIFICATION AND CHARACTERIZATION , 1967 .

[25]  G. Mackaness,et al.  HOST-PARASITE RELATIONS IN MOUSE TYPHOID , 1966, The Journal of experimental medicine.

[26]  G. Mackaness,et al.  INFECTION-IMMUNITY IN EXPERIMENTAL SALMONELLOSIS , 1966, The Journal of experimental medicine.

[27]  G. Mackaness,et al.  MECHANISMS OF ACQUIRED RESISTANCE IN MOUSE TYPHOID , 1966, The Journal of experimental medicine.

[28]  M. T. Ashcroft,et al.  CONTROLLED FIELD TRIAL IN BRITISH GUIANA SCHOOL CHILDREN OF HEAT-KILLED-PHENOLIZED AND ACETONE-KILLED LYOPHILIZED TYPHOID VACCINES. , 1964, American journal of hygiene.

[29]  L. H. Muschel,et al.  THE BACTERICIDAL ACTIONS OF O AND VI ANTIBODIES AGAINST SALMONELLA TYPHOSA. , 1964, Journal of Immunology.

[30]  T. Fukasawa,et al.  Galactose-sensitive mutants of Salmonella. II. Bacteriolysis induced by galactose. , 1961, Biochimica et biophysica acta.

[31]  H. Nikaido,et al.  Galactose-sensitive mutants of Salmonella. I. Metabolism of galactose. , 1961, Biochimica et biophysica acta.

[32]  H. Kalckar,et al.  HEREDITARY DEFECTS IN GALACTOSE METABOLISM IN ESCHERICHIA COLI MUTANTS, I. DETERMINATION OF ENZYME ACTIVITIES. , 1959, Proceedings of the National Academy of Sciences of the United States of America.

[33]  T. Fukasawa,et al.  Galactose-sensitive Mutants of Salmonella , 1959, Nature.

[34]  M. Crumpton,et al.  The serological specificities of Pasteurella pseudotuberculosis somatic antigens. , 1958, Journal of general microbiology.

[35]  R. Reitler,et al.  The Occurrence of Typhoid Bacilli Containing Vi Antigen in Cases of Typhoid Fever and of Vi Antibody in their Sera , 1935, Journal of Hygiene.

[36]  S. Bhatnagar,et al.  Observations on the Properties of the Vi Antigen of B. typhosus. , 1934 .

[37]  R. Pitt,et al.  A NEW ANTIGEN OF B. TYPHOSUS: ITS RELATION TO VIRULENCE AND TO ACTIVE AND PASSIVE IMMUNISATION , 1934 .

[38]  R. Pitt,et al.  Virulence of B. typhosus and Resistance to O Antibody. , 1934 .

[39]  E. Fuerer,et al.  Characteristics of the attenuated oral vaccine strain "S. typhi" Ty 21a. , 1983, Developments in biological standardization.

[40]  C. Serié,et al.  A controlled field trial of liver oral typhoid vaccine Ty21a. , 1980, Bulletin of the World Health Organization.

[41]  S. Berman,et al.  The effect of adding iron to mucin on the enhancement of virulence for mice of Salmonella typhi strain TY 2. , 1980, Journal of biological standardization.

[42]  Jeffrey H. Miller.  Experiments in molecular genetics , 1972 .

[43]  A. B. CiusnE,et al.  Typhoid fever. , 1967, The Journal of the Arkansas Medical Society.

[44]  S. Saito,et al.  Galactose 1-phosphate uridylyltransferase of Escherichia coli. II. Further purification and characterization. , 1967, The Journal of biological chemistry.

[45]  Blake Jb.  EVALUATION OF TYPHOID VACCINES IN THE LABORATORY AND IN A CONTROLLED FIELD TRIAL IN POLAND. PRELIMINARY REPORT. , 1965 .

[46]  L. Stuhl,et al.  A CONTROLED FIELD TRIAL OF THE EFFECTIVENESS OF ACETONE-DRIED AND INACTIVATED AND HEAT-PHENOL-INACTIVATED TYPHOID VACCINES IN YUGOSLAVIA. , 1964, Bulletin of the World Health Organization.